
Galecto Inc (DMRA) Stock Forecast & Price Target
Galecto Inc (DMRA) Analyst Ratings
Bulls say
Damora Therapeutics is expected to see success with its pipeline products, notably DMR-001, due to the potential for higher pricing and a unique profile that may appeal to a broader patient population. The company also has a strong management team led by CEO Ms. Jarrett, which brings expertise and experience in the life sciences industry. The success of DMR-001 may also disrupt the market and compete with current standards of treatment, such as Incyte's JAK inhibitors, providing a potential area for growth in a crucial medical need for disease-modifying options.
Bears say
Damora Therapeutics is facing a difficult road ahead as they aim to revolutionize care for people with hematologic disorders through the development of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms. However, key factors such as target engagement, VAF reduction, and patient outcomes may not be reached in their Phase 3 initiation in 2028, and competition from incumbents and next-generation therapies could weaken their position. Despite their promising pipeline, early data and financial metrics suggest a challenging road to success, with the potential for disappointing POC readouts and cash burn in the coming years.
This aggregate rating is based on analysts' research of Galecto Inc and is not a guaranteed prediction by Public.com or investment advice.
Galecto Inc (DMRA) Analyst Forecast & Price Prediction
Start investing in Galecto Inc (DMRA)
Order type
Buy in
Order amount
Est. shares
0 shares